Navigation Links
UCSF symposium considers biomedical approaches to HIV/AIDS prevention
Date:2/13/2009

New and emerging biomedical approaches to HIV/AIDS prevention will be the focus of a daylong symposium on February 24 sponsored by the UCSF-Gladstone Institute for Virology and Immunology Center for AIDS Research (CFAR) and the UCSF Center for AIDS Prevention Studies.

"Defining new biomedical approaches capable of curbing the global HIV epidemic is a high priority. This symposium will provide a timely overview of the most promising advances," said Warner C. Greene, MD, PhD, director of the Gladstone Institute for Virology and Immunology (GIVI) and co-director of the UCSF-GIVI CFAR.

Use of antiretrovirals for HIV prevention in uninfected individuals at high risk for infection, herpes suppression, male circumcision and the successful treatment of HIV-infected individuals with antiretrovirals are some of the approaches that will be under discussion at the symposium.

"With the setbacks in HIV vaccine development and a still expanding epidemic, we are forced to consider all options to prevent HIV transmission. Along with ongoing and critical efforts to understand and reduce behaviors of risk, we are deeply interested in how biologic barriers may be employed in effective prevention," said Paul A. Volberding, MD, UCSF-GIVI CFAR co-director and professor and vice-chair, UCSF Department of Medicine.

"Antiretroviral therapies are extremely potent and convenient in reducing HIV replication and might be part of a comprehensive effort to couple treatment with prevention. In selected situations, antiretroviral therapy may be used solely as prevention in persons otherwise unable to avoid potential exposure to infection. These and other topics promise to generate a lively and informative debate," added Volberding.

In addition to examining biomedical approaches, the symposium will address topics related to the conduct of clinical trials investigating these approaches and issues associated with implementation and scale-up of biomedical prevention interventions once they have been proven effective in clinical trials.

"Understanding the impact of behavioral issues such as consistent pill-taking or proper product usage as well as the difficulties of measuring these through trial participants' self reporting is crucial to successfully conducting clinical trials of biomedical approaches," said Stephen F. Morin, professor of medicine and director of the UCSF Center for AIDS Prevention Studies (CAPS).

"Moreover, the symposium will address the social science components involved in the implementation and scale-up of interventions following positive results in a clinical trial. For instance, male circumcision trials have shown success in preventing HIV acquisition but, as we will discuss, there are significant cultural, social and behavioral considerations that must be addressed if the intervention is going to be successfully implemented," said Morin.

The symposium will be held at UCSF's Mission Bay campus at the Mission Bay Conference Center beginning at 9 a.m. The full program can be found, along with information about parking, mass transit and registration online at http://cfar.ucsf.edu/Symposium2009. The event is free, though registration is required.


'/>"/>

Contact: Jeff Sheehy
jsheehy@ari.ucsf.edu
415-396-8165
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
2. Upcoming Packard/Stanford Autism Symposium a Catalyst for Collaboration among Researchers and Community
3. La Rabida Children's Hospital's 13th Annual Symposium to Discuss Outcomes of Premature Birth
4. SNMs Mid-Winter Educational Symposium for nuclear medicine and molecular imaging professionals
5. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
6. Bionovo to Present Recent Findings of BN108, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
7. Cosmetic Bootcamp Marketing and Management Symposium to Begin Tomorrow
8. Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium
9. Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium
10. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
11. Interim HealthCare Recognizes Outstanding Franchisees at National Clinical Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... weeks Nature’s Tears® EyeMist®, the signature product of her research center at Bio-Logic ... the world’s largest population and the greatest number of sufferers of blindness. “We ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... may give insight into why concussion rates are on the rise, say researchers ... Annual Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... and application performance monitoring (APM) solutions, has expanded its footprint inside the ... According to Peter Ohrenberger, sales director at Nastel, “We’ve replaced an existing ...
(Date:7/20/2017)... ATLANTA, Ga. (PRWEB) , ... July 20, 2017 , ... ... and equal access to medicine for everyone affected by diabetes, is teaming up with ... the five-day global event kicks off on July 24th. , “Team Type 1’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata ... and boosting quality. , It’s known as the “CY2016 Annual FDA Medical Device ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... 20, 2017  Prime Therapeutics LLC (Prime) released this statement ... following today,s Institute for Clinical and Economic Review,s (ICER) ... effectiveness and value of abuse-deterrent formulations (ADF) of opioids. Prime ... at the meeting. ... benefit to the use of abuse-deterrent formulations (ADF) in opioids ...
(Date:7/15/2017)... 15, 2017 Enterin Inc., a Philadelphia ... disease (PD), today announced the completion of a $12.7 million ... Ventures III, as well as the participation of existing investors. ... to have the support of New Ventures III and our ... validation of the potential of our platform technology to transform ...
(Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ...
Breaking Medicine Technology: